NeuroSense Secures South Korean Patent for PrimeC: A Breakthrough in ALS Treatment

In a significant advancement in the battle against amyotrophic lateral sclerosis (ALS), NeuroSense Therapeutics Ltd. has been granted a South Korean patent for its lead drug candidate, PrimeC. This late-stage biotechnology firm is focused on developing cutting-edge therapies to combat severe neurodegenerative diseases, and with this patent, it aims to solidify its standing in the competitive pharmaceutical landscape.

On June 11, 2026, the Korean Intellectual Property Office awarded Patent Number 10-2969898 to NeuroSense, covering crucial elements associated with PrimeC. This includes not only its unique tablet formulation but also its manufacturing process and pharmacokinetic attributes that aid in its effectiveness against ALS. With this achievement, PrimeC is now protected in South Korea until 2042, allowing NeuroSense to enhance its strategic positioning in one of the world's most significant pharmaceutical markets.

Alon Ben-Noon, the CEO of NeuroSense, expressed that this patent is a testament to the innovative nature of PrimeC and signifies a pivotal step for the company as it progresses towards Phase 3 clinical trials. He emphasized that South Korea represents a critical market, and this milestone underscores the proprietary aspects of their groundbreaking therapy.

The granting of this patent comes on the heels of similar approvals in other countries, such as Japan, Brazil, Australia, and the United States. This expansion of NeuroSense's global patent portfolio is crucial as the company gears up to initiate pivotal clinical studies, which could further propel PrimeC into the forefront of ALS treatment options.

PrimeC is an advanced oral therapy designed to target multiple biological mechanisms linked to ALS progression. It specifically addresses issues like neuroinflammation, oxidative stress, and dysregulated iron metabolism—factors that significantly contribute to the disease's deterioration.

The company previously reported encouraging results from its Phase 2b trial, known as the PARADIGM study. These results revealed not only a meaningful delay in disease progression but also demonstrated significant biological activity across various ALS-related biomarkers. Long-term follow-up data indicated a notable survival benefit, suggesting that PrimeC could potentially change the course of treatment for ALS patients.

As it stands, NeuroSense has already received clearance from the U.S. Food and Drug Administration (FDA) to launch its pivotal Phase 3 PARAGON study, which is expected to enroll around 300 participants primarily based in the United States. This marks a hopeful progression as the company aims to address a disease that, annually, affects over 5,000 individuals in the U.S., carrying a considerable societal and economic burden.

With ALS representing a significant challenge—often leading to complete paralysis and death within a few years of diagnosis—the implications of effective therapies like PrimeC cannot be overstated. By targeting multiple pathways involved in neuron degeneration, PrimeC not only offers potential relief but signifies a hopeful avenue of research in neurodegenerative diseases overall.

As NeuroSense continues to advance its research and development efforts, this latest patent in South Korea adds another layer of credibility to its initiatives. Investors and stakeholders will be watching closely as the company embarks on this next chapter, hoping to bring light to the lives of those affected by ALS.

For more updates on NeuroSense and its journey with PrimeC, interested parties are invited to check out their website and follow their journey on LinkedIn, YouTube, and X. Continuous information updates will be shared, keeping investors informed about the ongoing developments within this promising sphere of biotechnology.